Swain 23 Oct. 02 1 Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)

Slides:



Advertisements
Similar presentations
V.: 9/7/2007 AC Submit1 Statistical Review of the Observational Studies of Aprotinin Safety Part I: Methods, Mangano and Karkouti Studies CRDAC and DSaRM.
Advertisements

Steroids In caRdiac Surgery (SIRS) Trial
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
ECLIPSE Trial: Ensure’s Vascular Closure Device Speeds Hemostasis S. Chiu Wong MD Director, Cardiac Catheterization Laboratories New York Presbyterian.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Clinical Trial Efficacy Senior Biostatistician Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, Connecticut James Street, PhD.
InFUSE ™ Bone Graft / LT-CAGE ™ Lumbar Tapered Fusion Device IDE Clinical Results G Hallett H. Mathews, M.D. Richmond, Virginia.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
5 Years Results of Off-Pump VS On-Pump CABG 5 Years Results of Off-Pump VS On-Pump CABG Prospective Non-randomized Comparative Study Piya Cherntanomwong*,
Randomized Evaluation of Long- term anticoagulant therapY Dabigatran Compared to Warfarin in 18,113 Patients with Atrial Fibrillation at Risk of Stroke.
12/10/02Harry Bushar1 Computerized Thermal Imaging Breast Cancer System 2100 (CTI BCS2100) Radiological Devices Advisory Panel December 10, 2002 Statistical.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Kenneth W. Mahaffey, Zhen Huang, Pierluigi Tricoci, Frans Van de Werf, Harvey D. White, Paul W. Armstrong, Claes Held, Sergio Leonardi, Philip E. Aylward,
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
Clinical Outcomes with Newer Antihyperglycemic Agents
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
DHHS / FDA / CDRH 1 Circulatory Support Devices Panel Tuesday, September 11, 2001 CoSeal® Surgical Sealant P
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Clinical Review Barbara Buch, M.D. Orthopaedic Surgeon FDA Orthopaedic Devices Branch.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
The Diabetic Retinopathy Clinical Research Network
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators Disclosures.
Limbs International Medical Buflomedil Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Alain Leizorovicz LIMB.
Laser-Ranibizumab-Triamcinolone for DME Study DRCR.net Protocol I
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
Terutroban versus aspirin in Patients with Cerebral Ischaemic Events (PREFORM): a Randomized, Double- blind Parallel-group Trial Daniel Wells Mercer University.
Axel Linke University of Leipzig Heart Center, Leipzig, Germany Sabine Bleiziffer German Heart Center, Munich, Germany Johan Bosmans University Hospital.
Safety of Cyclooxygenase-2 (COX-2) inhibitors, Valdecoxib and Parecoxib, versus Placebo for Post CABG Pain Management Presented at American College of.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An International Randomised Evaluation One year follow-up.
Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.
Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.
UC c EN. Through Medtronic sponsored research, the Transcatheter Aortic Valves clinical portfolio is studying over 11,000 subjects at over 125.
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial PEACE Trial Presented at The American Heart Association Scientific Sessions.
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
1 Pre-Specified Outcomes All primary and secondary outcomes and their components were pre-specified, i.e., they appeared in the protocol, manual of operations.
ARNO TRIAL (Antithrombotic Regimens aNd Outcome) A RANDOMIZED TRIAL COMPARING BIVALIRUDIN WITH UNFRACTIONED HEPARIN IN PATIENTS UNDERGOING ELECTIVE PCI.
1 Statistical Review of the Observational Studies of Aprotinin Safety Part II: The i3 Drug Safety Study CRDAC and DSaRM Meeting September 12, 2007 P. Chris.
Phase 2 Evaluation of Intravitreal Bevacizumab for DME Sponsored by the National Eye Institute, National Institutes of Health, U.S. Department of Health.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Circulatory System Devices Panel Questions for Discussion EMBOL·X Aortic Filter October 23, 2002.
Safety, Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines: The Phase 2 BELMONT Study Authors:
2-Year Outcomes following Surgical Treatment of Moderate Ischemic Mitral Regurgitation: The Cardiothoracic Surgical Trials Network Robert E. Michler,
Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty:
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
RAVEL 4 YEAR FOLLOW-UP - Cordis Cardiology / Cardialysis – Euro-PCR – Sousa – 24 May 2005 RAVEL A RAndomised, double-blind study with the Sirolimus-eluting.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
David J McCormack MFSTEd FRCSEd (CTh) Advanced Clinical Fellow
Nephrology Journal Club The SPRINT Trial Parker Gregg
Early Surgery versus Conventional Treatment for Infective Endocarditis
Update on the Watchman Device CRT 2010 Washington, DC
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
Axel Linke University of Leipzig Heart Center, Leipzig, Germany
Randomized Clinical Trial Jeffrey G. Gross, M.D. for the DRCR Network
Jeff Macemon Waikato Cardiothoracic Unit
Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.
Hallett H. Mathews, M.D. Richmond, Virginia
Atlantic Cardiovascular Patient Outcomes Research Team
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing.
2019 Joint Statistical Meetings at Denver
Presentation transcript:

Swain 23 Oct Embol-X Clinical Reviewers Wolf Sapirstein M.D. Julie Swain M.D. (Cardiothoracic Surgery)

Swain 23 Oct Study Design Randomized, multicenter Control 644 patients, Filter 645 patients Control arm = patients without filter Interim data analysis at 50% of patients

Swain 23 Oct Investigational Plan “If the hypothesis tests performed at the interim are statistically significant, indicating emboli capture and equivalent safety, the study will be terminated” The study was continued to completion to attempt to show safety superiority (which was not shown)

Swain 23 Oct Inclusion/Exclusion Criteria Elective operations Isolated CAB or valve Age >60 Total 24 exclusion criteria – Neurological deficit – Hx major stroke (as defined by a clinical history of fixed, focal neurological deficit attributable to stroke) – Redo operations – Renal failure on dialysis

Swain 23 Oct Neurological Evaluation (Gross Neurologic Testing) History, Physical Exam NIH Stroke Score No neuropsychological testing

Swain 23 Oct Endpoints Efficacy: >75% of filters trap at least one particle Composite Primary Safety: 12 items (Not worse than control group with an equivalency delta of 5%) Secondary Safety: Aortic Injury (not part of composite safety endpoint)

Swain 23 Oct Patient Demographics No statistical differences in baseline characteristics between treatment and control group Treatment group: – 73% male –91% Caucasian –Average age 71 years

Swain 23 Oct Types of operations CABG AVR MVR/R 8% 6% 84%

Swain 23 Oct Composite Safety Endpoint (12 clinical events) Death Neurological Stroke TIA Non-metabolic coma Renal Creatinine >2.0 or increased 50% (non-dialysis) Dialysis Gastrointestinal Bleeding requiring transfusion Pancreatitis Cholecystitis Mesenteric ischemia Cardiac Q-wave MI Non Q-wave MI Limb threatening periph. embolism Diminished pulse Altered pallor Pain

Swain 23 Oct Number of Particles Trapped % filters >20 Maximum number trapped = 25 (38 in roll-in) Total number of particles embolized unknown Mean 5.6 particles/filter

Swain 23 Oct Selected Events % patients * * P <.001

Swain 23 Oct Manipulation-Related Aortic Injury Filter Roll In Filter Control % patients * * p<0.001 vs control 7/7842/456 9/454

Swain 23 Oct Manipulation-Related Aortic Injury Occurred in 9.2% of filter patients (42/456 patients) 3 filter patients required aortic repair Study protocol follow-up: 30 day or hospital discharge, whichever occurred first (median follow-up 7.0 days) Post hoc designed telephone follow-up of 43/49 aortic injury patients (roll in + randomized), 18/49 had > 1 year follow-up No apparent training effect Not associated with increase in Adverse Events

Swain 23 Oct Post-Hoc Data Analysis These analyses were not planned prospectively in the investigational plan Statistical treatment of post hoc analyses is not straight-forward  Nominal p-values do not account for multiplicity  No way to know how much adjustment should be applied when judging "significance"

Swain 23 Oct Selected Adverse Events (Higgins score >5) % patients p = N.S. for all points

Swain 23 Oct Summary Embol-XControlp value Trapped at least one particle 97% Composite safety endpoint 17.1%18.9%n.s. Individual safety eventsn.s. Aortic injuries9.2%2.0%<.001

Swain 23 Oct Conclusions The filter traps particles A correlation with clinical improvement was not shown Additional concerns were raised by the occurrence of aortic injuries